sar425899 dual agonist glp-1 glucagon sanofi Emerging incretin- and multi- agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond The Road Superfood obesitymedicine #medicare #glp1 #patientaccess Supply Options:6 Month Supply

sar425899 dual agonist glp-1 glucagon sanofi Emerging incretin- and multi- agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond The Road Superfood obesitymedicine #medicare #glp1 #patientaccess Supply Options:6 Month Supply

obesitymedicine #medicare #glp1 #patientaccess #priorauthorization | Joseph Zucchi, PA-C, MPAS | 34 comments

Additionally, some patients report improved quality of life related to better glucose control, weight loss, and the convenience of once-weekly dosing options

Superfood

Supply Options:6 Month Supply

2018;314:E287–E295